Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 3/20 | 0.37 |
| ▸ | USP19 | O94966 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | YEATS4 | O95619 | 4/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30747621 | 0.99 | HTR4 (0.36) | HTR4USP19KCNH2YEATS4TMEM97 | |
| SCHEMBL30747620 | 0.91 | HTR4 (0.41) | HTR4USP19KCNH2YEATS4 | |
| SCHEMBL31553344 | 0.86 | USP19 (0.33) | USP19 | |
| SCHEMBL30747594 | 0.84 | ADORA2A (0.33) | — | |
| SCHEMBL30747719 | 0.84 | OPRL1 (0.36) | — | |
| SCHEMBL30747567 | 0.82 | MET (0.36) | — | |
| SCHEMBL30747592 | 0.79 | CCR3 (0.43) | — | |
| SCHEMBL30747675 | 0.79 | ROCK2 (0.34) | USP19 | |
| SCHEMBL30747498 | 0.79 | HRH3 (0.39) | KCNH2 | |
| SCHEMBL31553349 | 0.78 | MTOR (0.33) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539938-A1 | PYRIDAZINONE-DERIVED COMPOUNDS FOR THE MODULATION OF MYC AND FOR MEDICAL USES | Genetic Intelligence, Inc (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023245091-A1 | PYRIDAZINONE-DERIVED COMPOUNDS FOR THE MODULATION OF MYC AND FOR MEDICAL USES | Genetic Intelligence, Inc (US) | 2023-12-21 | — | — | WO | disclosed |